Antispastic therapy with botulinum toxin type A in patients with traumatic spinal cord lesion

Objectives: The purpose of this study was to determine the effect of botulinum toxin injections for the treatment of spasticity after traumatic spinal cord injury. Methods: 9 patients were included in this prospective designed study, with a follow-up of at least 2 years. All patients suffered from...

Full description

Bibliographic Details
Main Authors: Spiegl, Ulrich J., Maier, Doris, Gonschorek, Oliver, Heyde, Christoph-Eckhard, Bühren, Volker
Format: Article
Language:deu
Published: German Medical Science GMS Publishing House 2014-12-01
Series:GMS Interdisciplinary Plastic and Reconstructive Surgery DGPW
Subjects:
Online Access:http://www.egms.de/static/en/journals/iprs/2014-3/iprs000055.shtml
id doaj-bc5a237480eb4ac1adc371ccc9dfc310
record_format Article
spelling doaj-bc5a237480eb4ac1adc371ccc9dfc3102020-11-25T02:07:52ZdeuGerman Medical Science GMS Publishing HouseGMS Interdisciplinary Plastic and Reconstructive Surgery DGPW2193-80912014-12-013Doc1410.3205/iprs000055Antispastic therapy with botulinum toxin type A in patients with traumatic spinal cord lesionSpiegl, Ulrich J.0Maier, Doris1Gonschorek, Oliver2Heyde, Christoph-Eckhard3Bühren, Volker4Berufsgenossenschaftliche Unfallklinik – Traumacenter Murnau, GermanyBerufsgenossenschaftliche Unfallklinik – Traumacenter Murnau, GermanyBerufsgenossenschaftliche Unfallklinik – Traumacenter Murnau, GermanyDepartment of Orthopedic and Trauma Surgery, University of Leipzig, GermanyBerufsgenossenschaftliche Unfallklinik – Traumacenter Murnau, GermanyObjectives: The purpose of this study was to determine the effect of botulinum toxin injections for the treatment of spasticity after traumatic spinal cord injury. Methods: 9 patients were included in this prospective designed study, with a follow-up of at least 2 years. All patients suffered from a massive spasticity after traumatic spinal cord lesion. Conservative treatment options did not show satisfying results. All patients were injected a maximal dose of 2,000 units of botulinum toxin A in no more than keletal muscle groups. Clinical control examinations were performed after 2 weeks and after at least 2 years. Results: 6 patients reported a good or very good result. One patient offered increasing difficulty in walking for a short time after injection. 2 patients showed no beneficial effects. One patient experienced a modest temporary general weakness for 3 days. After 2 years, 3 patients showed improved function with persistent reduction of spasticity. In the other cases, the beneficial effect lasted for an average of 9 months. Conclusion: Botulinum toxin A injection seems to be an effective complementary therapy option in the treatment of spasticity of paraplegic patients with complete deficit of their motor function (ASIA A and B) and a spastic distribution pattern, effecting only a limited number of muscle groups. Caution has to be recommended for incomplete paretic patients, who are able to walk.http://www.egms.de/static/en/journals/iprs/2014-3/iprs000055.shtmlbotulinum toxinspacticitytraumatic spinal cord lesion
collection DOAJ
language deu
format Article
sources DOAJ
author Spiegl, Ulrich J.
Maier, Doris
Gonschorek, Oliver
Heyde, Christoph-Eckhard
Bühren, Volker
spellingShingle Spiegl, Ulrich J.
Maier, Doris
Gonschorek, Oliver
Heyde, Christoph-Eckhard
Bühren, Volker
Antispastic therapy with botulinum toxin type A in patients with traumatic spinal cord lesion
GMS Interdisciplinary Plastic and Reconstructive Surgery DGPW
botulinum toxin
spacticity
traumatic spinal cord lesion
author_facet Spiegl, Ulrich J.
Maier, Doris
Gonschorek, Oliver
Heyde, Christoph-Eckhard
Bühren, Volker
author_sort Spiegl, Ulrich J.
title Antispastic therapy with botulinum toxin type A in patients with traumatic spinal cord lesion
title_short Antispastic therapy with botulinum toxin type A in patients with traumatic spinal cord lesion
title_full Antispastic therapy with botulinum toxin type A in patients with traumatic spinal cord lesion
title_fullStr Antispastic therapy with botulinum toxin type A in patients with traumatic spinal cord lesion
title_full_unstemmed Antispastic therapy with botulinum toxin type A in patients with traumatic spinal cord lesion
title_sort antispastic therapy with botulinum toxin type a in patients with traumatic spinal cord lesion
publisher German Medical Science GMS Publishing House
series GMS Interdisciplinary Plastic and Reconstructive Surgery DGPW
issn 2193-8091
publishDate 2014-12-01
description Objectives: The purpose of this study was to determine the effect of botulinum toxin injections for the treatment of spasticity after traumatic spinal cord injury. Methods: 9 patients were included in this prospective designed study, with a follow-up of at least 2 years. All patients suffered from a massive spasticity after traumatic spinal cord lesion. Conservative treatment options did not show satisfying results. All patients were injected a maximal dose of 2,000 units of botulinum toxin A in no more than keletal muscle groups. Clinical control examinations were performed after 2 weeks and after at least 2 years. Results: 6 patients reported a good or very good result. One patient offered increasing difficulty in walking for a short time after injection. 2 patients showed no beneficial effects. One patient experienced a modest temporary general weakness for 3 days. After 2 years, 3 patients showed improved function with persistent reduction of spasticity. In the other cases, the beneficial effect lasted for an average of 9 months. Conclusion: Botulinum toxin A injection seems to be an effective complementary therapy option in the treatment of spasticity of paraplegic patients with complete deficit of their motor function (ASIA A and B) and a spastic distribution pattern, effecting only a limited number of muscle groups. Caution has to be recommended for incomplete paretic patients, who are able to walk.
topic botulinum toxin
spacticity
traumatic spinal cord lesion
url http://www.egms.de/static/en/journals/iprs/2014-3/iprs000055.shtml
work_keys_str_mv AT spieglulrichj antispastictherapywithbotulinumtoxintypeainpatientswithtraumaticspinalcordlesion
AT maierdoris antispastictherapywithbotulinumtoxintypeainpatientswithtraumaticspinalcordlesion
AT gonschorekoliver antispastictherapywithbotulinumtoxintypeainpatientswithtraumaticspinalcordlesion
AT heydechristopheckhard antispastictherapywithbotulinumtoxintypeainpatientswithtraumaticspinalcordlesion
AT buhrenvolker antispastictherapywithbotulinumtoxintypeainpatientswithtraumaticspinalcordlesion
_version_ 1724929112850563072